Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3): An AIO phase II study (EVINEC)

被引：1
|
作者：
Pavel, M. E. [1 ]
von Weikersthal, L. Fischer [2 ]
Kloeppel, G. [3 ]
Krause, K. [4 ]
Apostolidis, L. [5 ]
机构：
[1] Univ Klin Erlangen, Endocrinol Dept, Gastroenterol & Hepatol, Erlangen, Germany
[2] Klinikum St Marien Amberg, Onkolog Zentrum, Amberg, Germany
[3] Tech Univ Munich, Inst Pathol, Munich, Germany
[4] AIO Studien gGmbH, Project Management Dept, Berlin, Germany
[5] Natl Ctr Tumor Dis NCT, Dept Med Oncol, Heidelberg, Germany
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.717
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1184MO
引用
收藏
页码：S702 / S702
页数：1
相关论文
共 50 条
  • [31] Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
    Carlsen, Esben Andreas
    Fazio, Nicola
    Granberg, Dan
    Grozinsky-Glasberg, Simona
    Ahmadzadehfar, Hojjat
    Grana, Chiara Maria
    Zandee, Wouter T.
    Cwikla, Jaroslaw
    Walter, Martin A.
    Oturai, Peter Sandor
    Rinke, Anja
    Weaver, Andrew
    Frilling, Andrea
    Gritti, Sara
    Arveschoug, Anne Kirstine
    Meirovitz, Amichay
    Knigge, Ulrich
    Sorbye, Halfdan
    ENDOCRINE-RELATED CANCER, 2019, 26 (02) : 227 - 239
  • [32] Treatment outcomes for well differentiated grade 3 neuroendocrine tumors (NET G3)
    Apostolidis, L.
    Jaeger, D.
    Winkler, E. C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] Transformation to High Grade 3 (G3) Neuroendocrine Neoplasia (NEN) - Molecular Imaging, Pathologic Features and Patient Outcomes
    Kong, G.
    Callahan, J.
    Prall, O.
    Michael, M.
    Hicks, R.
    NEUROENDOCRINOLOGY, 2020, 110 : 261 - 261
  • [34] Characterizing Immunophenotyping Changes with Pembrolizumab (P) Therapy in Grade 3 Neuroendocrine Neoplasms (G3 NENs)
    Yeung, H. M.
    Macfarlane, A.
    Campbell, K.
    Ruth, K.
    Gong, Y.
    Engstrom, P.
    Dasari, A.
    Vijayvergia, N.
    NEUROENDOCRINOLOGY, 2019, 108 : 194 - 194
  • [35] Pegasys As A Second Line of Effective Treatment Plan for G3 Non Responders of Conventional Therapy
    Arshad, Binish G.
    Raza, Abida
    Shakeel, Samina
    Anwar, Muhammad A.
    ANTIVIRAL RESEARCH, 2011, 90 (02) : A53 - A53
  • [36] Invited Editorial on Surgical Treatment of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: Pay Close Attention to the Pathology Report
    Pommier, Rodney F.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (01) : 12 - 14
  • [37] Invited Editorial on Surgical Treatment of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: Pay Close Attention to the Pathology Report
    Rodney F. Pommier
    Annals of Surgical Oncology, 2023, 30 : 12 - 14
  • [38] Prognostic and predictive factors of platinum-based chemotherapy in gastroenteropancreatic neuroendocrine neoplasms G3
    Kolasinska-Cwikla, A.
    Cwikla, J.
    Roszkowska-Purska, K.
    Samsel, R.
    Cichocki, A.
    Palucki, J.
    Wyrwicz, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S164 - S164
  • [39] Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.
    Chan, David
    Bergsland, Emily K.
    Chan, Jennifer A.
    Gadgil, Rujuta
    Halfdanarson, Thorvardur Ragnar
    Hornbacker, Kathleen
    Kelly, Virginia
    Kunz, Pamela L.
    McGarrah, Patrick Walsh
    Raj, Nitya Prabhakar
    Reidy, Diane Lauren
    Thawer, Alia
    Whitman, Julia
    Wu, Linda
    Singh, Simron
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [40] High Grade (G3) Neuroendocrine Neoplasms Should Be Further Classified According to Morphological Differentiation
    Mandair, D.
    O'Leary, J.
    Luong, T., V
    Thirlwell, C.
    Meyer, T.
    Caplin, M.
    Toumpanakis, C.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 303 - 303
12345